Mark Yamanaka31 Cloudcrest, Laguna Beach, CA 92656

Mark Yamanaka Phones & Addresses

31 Cloudcrest, Aliso Viejo, CA 92656

4111 Parkside Pl, Carlsbad, CA 92008 (760) 720-1756

3231 Waring Rd, Oceanside, CA 92056 (760) 941-0221

Orange, CA

Work

Company: TRI-CITY PULMONARY MEDICAL GRP Address: 3231 Waring Ct Suite D, Oceanside, CA 92056 Phones: (760) 758-7402 (Phone) (760) 758-1980 (Fax)

Education

School / High School: University of California At Irvine / California College of Medicine & Surgery 1981

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Critical Care Medicine, 1989

Emails

Mentions for Mark Yamanaka

Career records & work history

Medicine Doctors

Mark Yamanaka Photo 1

Dr. Mark K Yamanaka, Oceanside CA - MD (Doctor of Medicine)

Specialties:
Critical Care Medicine
Pulmonology
Address:
TRI-CITY PULMONARY MEDICAL GRP
3231 Waring Ct Suite D, Oceanside, CA 92056
(760) 758-7402 (Phone) (760) 758-1980 (Fax)
Certifications:
Critical Care Medicine, 1989
Internal Medicine, 1984
Pulmonary Disease, 1986
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
TRI-CITY PULMONARY MEDICAL GRP
3231 Waring Ct Suite D, Oceanside, CA 92056
Tri - City Medical Center
4002 Vista Way, Oceanside, CA 92056
Education:
Medical School
University of California At Irvine / California College of Medicine & Surgery
Graduated: 1981
Medical School
La Co Harbor UCLA Med Center
Graduated: 1981
Medical School
St Mary Med Center
Graduated: 1981
Mark Yamanaka Photo 2

Mark Ko Yamanaka, Oceanside CA

Specialties:
Internal Medicine
Pulmonary Disease
Cardiovascular Disease
Work:
Medical Office
3231 Waring Ct, Oceanside, CA 92056
Education:
University of California at Davis (1981)

Mark Yamanaka resumes & CV records

Resumes

Mark Yamanaka Photo 31

Mark Yamanaka

Mark Yamanaka Photo 32

Professional

Location:
United States

Publications & IP owners

Us Patents

Alpha5-Beta1 Antibodies And Their Uses

US Patent:
8399647, Mar 19, 2013
Filed:
Sep 20, 2011
Appl. No.:
13/237502
Inventors:
Steven L. Bender - Oceanside CA, US
Gerald F. Casperson - Ballwin MO, US
Xin Jiang - San Diego CA, US
Gang Li - San Diego CA, US
Michael A. North - Rancho Santa Fe CA, US
Jianying Wang - San Diego CA, US
Grant Wickman - Glasgow, GB
Peter Brams - Sacramento CA, US
Haichun Huang - Fremont CA, US
Brigitte Devaux - Palo Alto CA, US
Haibin Chen - Sunnyvale CA, US
Dawn M. Tanamachi - Miltpitas CA, US
Kristopher Toy - San Jose CA, US
Lan Yang - Morgan Hill CA, US
Tim W. Sproul - Livermore CA, US
Mark Yamanaka - Pleasanton CA, US
Assignee:
Pfizer Inc. - New York NY
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
C07H 21/04
C12P 21/06
C12N 15/87
C12N 1/20
C12N 15/74
US Classification:
536 2353, 435 691, 435455, 4352523, 4353201
Abstract:
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein.

Human Antibodies That Bind Cd22 And Uses Thereof

US Patent:
8481683, Jul 9, 2013
Filed:
Nov 30, 2007
Appl. No.:
12/517183
Inventors:
David John King - Solana Beach CA, US
Alison Witte - Scotts Valley CA, US
Heidi N. LeBlanc - Mountain View CA, US
Richard Theolis - Santa Cruz CA, US
Asna Masood - Saratoga CA, US
Mark Yamanaka - Pleasanton CA, US
Kyra D. Zens - San Mateo CA, US
Sarah R. Reed - Santa Cruz CA, US
Tim Sproul - Livermore CA, US
David Passmore - Mountain View CA, US
Dawn M. Tanamachi - San Carlos CA, US
Kristopher Toy - San Jose CA, US
Assignee:
Medarex, Inc. - Princeton NJ
International Classification:
C12P 21/08
C07K 16/00
A61K 39/395
A61K 39/40
C07K 1/00
US Classification:
5303871, 5303873, 5303877, 5303881, 53038815, 53038822, 5303911, 5303913, 4241301, 4241331, 4241381, 4241411, 4241421, 4241431, 4241441, 4241521, 4241531, 4241551, 4241561, 4241781
Abstract:
The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.

Alpha 5 - Beta 1 Antibodies And Their Uses

US Patent:
2010033, Dec 30, 2010
Filed:
Feb 4, 2009
Appl. No.:
12/365638
Inventors:
STEVEN L. BENDER - OCEANSIDE CA, US
GERALD F. CASPERSON - BALLWIN MO, US
XIN JIANG - SAN DIEGO CA, US
GANG LI - SAN DIEGO CA, US
MICHAEL A. NORTH - RANCHO SANTA FE CA, US
JIANYING WANG - SAN DIEGO CA, US
GRANT WICKMAN - GLASGOW, GB
PETER BRAMS - SACRAMENTO CA, US
HAICHUN HUANG - FREMONT CA, US
BRIGITTE DEVAUX - PALO ALTO CA, US
HAIBIN CHEN - SUNNYVALE CA, US
DAWN M. TANAMACHI - MILPITAS CA, US
KRISTOPHER TOY - SAN JOSE CA, US
LAN YANG - MORGAN HILL CA, US
TIM W. SPROUL - LIVERMORE CA, US
MARK YAMANAKA - PLEASANTON CA, US
International Classification:
A61K 39/395
C07K 16/28
C07K 16/00
A61P 35/00
US Classification:
4241331, 5303873, 53038822, 5303891, 5303871, 4241431, 4241721, 4241301
Abstract:
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein.

Alpha5-Beta1 Antibodies And Their Uses

US Patent:
2014015, Jun 5, 2014
Filed:
Feb 21, 2013
Appl. No.:
13/772992
Inventors:
- ST. LOUIS MO, US
- MILPITAS CA, US
XIN JIANG - SAN DIEGO CA, US
GANG LI - SAN DIEGO CA, US
MICHAEL AIDAN NORTH - RANCHO SANTA FE CA, US
JIANYING WANG - SAN DIEGO CA, US
GRANT WICKMAN - GLASGOW, GB
PETER BRAMS - SACRAMENTO CA, US
HAICHUN HUANG - FREMONT CA, US
BRIGITTE DEVAUX - PALO ALTO CA, US
HAIBIN CHEN - SUNNYVALE CA, US
DAWN M. TANAMACHI - MILPITAS CA, US
KRISTOPHER TOY - SAN JOSE CA, US
LAN YANG - MORGAN HILL CA, US
TIM W. SPROUL - LIVERMORE CA, US
MARK YAMANAKA - PLEASANTON CA, US
Assignee:
PFIZER INC. - ST. LOUIS MO
BRISTOL-MYERS SQUIBB COMPANY - MILPITAS CA
International Classification:
C07K 16/28
US Classification:
4241741, 5303873, 5303897, 536 2353, 4353201, 435 696, 435375, 435334
Abstract:
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein.

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.